Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


17.07.2017

1 BMC Cancer
1 Eur J Obstet Gynecol Reprod Biol
9 Gynecol Oncol
1 Hum Pathol
1 J Natl Cancer Inst
3 Obstet Gynecol
1 Oncol Rep
3 Tumour Biol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. EOH KJ, Yoon JW, Lee JY, Nam EJ, et al
    A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy.
    BMC Cancer. 2017;17:481.
    PubMed     Text format     Abstract available


    Eur J Obstet Gynecol Reprod Biol

  2. CHENE G, Chauvy L, Buenerd A, Moret S, et al
    Dynamic real-time in vivo confocal laser endomicroscopy of the fallopian tube during laparoscopy in the prevention of ovarian cancer.
    Eur J Obstet Gynecol Reprod Biol. 2017;216:18-23.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  3. KRISTELEIT R, Davidenko I, Shirinkin V, El-Khouly F, et al
    A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
    Gynecol Oncol. 2017 Jul 8. pii: S0090-8258(17)31022.
    PubMed     Text format     Abstract available

  4. YUAN X, Zhang J, Li D, Mao Y, et al
    Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2017 Jul 8. pii: S0090-8258(17)31024.
    PubMed     Text format     Abstract available

  5. GREENWADE MM, Moore KN, Gillen JM, Ding K, et al
    Factors influencing clinical trial enrollment among ovarian cancer patients.
    Gynecol Oncol. 2017 Jul 6. pii: S0090-8258(17)30976.
    PubMed     Text format     Abstract available

  6. MATZ M, Coleman MP, Carreira H, Salmeron D, et al
    Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 396-404].
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30974.
    PubMed     Text format    

  7. SON JH, Chang SJ, Ryu HS
    Porta hepatis debulking procedures as part of primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30978.
    PubMed     Text format     Abstract available

  8. MATZ M, Coleman MP, Sant M, Chirlaque MD, et al
    Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 405-413].
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30973.
    PubMed     Text format    

  9. MENDERES G, Bonazzoli E, Bellone S, Black J, et al
    SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
    Gynecol Oncol. 2017 May 1. pii: S0090-8258(17)30804.
    PubMed     Text format     Abstract available

  10. COLON-OTERO G, Weroha SJ, Foster NR, Haluska P, et al
    Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
    Gynecol Oncol. 2017 Apr 28. pii: S0090-8258(17)30801.
    PubMed     Text format     Abstract available

  11. PALEARI L, Gandini S, Provinciali N, Puntoni M, et al
    Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis.
    Gynecol Oncol. 2017 Jul 10. pii: S0090-8258(17)30977.
    PubMed     Text format     Abstract available


    Hum Pathol

  12. SCHOOLMEESTER JK, Moyer AM, Goodenberger ML, Keeney GL, et al
    Pathologic Findings in Breast, Fallopian Tube and Ovary Specimens in non-BRCA Hereditary Breast and/or Ovarian Cancer Syndromes: A Study of 18 Patients with Deleterious Germline Mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH or CHEK2.
    Hum Pathol. 2017 Jul 11. pii: S0046-8177(17)30240.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  13. BRASKY TM, Felix AS, Cohn DE, McMeekin DS, et al
    Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.
    J Natl Cancer Inst. 2017;109:1-10.
    PubMed     Text format     Abstract available


    Obstet Gynecol

  14. SPENCER RJ, Hacker KE, Griggs JJ, Rice LW, et al
    Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous Ovarian Cancer Cytoreduction Surgery.
    Obstet Gynecol. 2017 Jul 7. doi: 10.1097/AOG.0000000000002140.
    PubMed     Text format     Abstract available

  15. MATSUO K, Machida H, Stone RL, Soliman PT, et al
    Risk of Subsequent Ovarian Cancer After Ovarian Conservation in Young Women With Stage I Endometrioid Endometrial Cancer.
    Obstet Gynecol. 2017 Jul 7. doi: 10.1097/AOG.0000000000002142.
    PubMed     Text format     Abstract available

  16. FAJAU-PREVOT C, Le Gac YT, Chevreau C, Cohade C, et al
    Ovarian Mucinous Cystadenoma After Ovarian Graft.
    Obstet Gynecol. 2017 May 5. doi: 10.1097/AOG.0000000000001990.
    PubMed     Text format     Abstract available


    Oncol Rep

  17. SATO M, Kawana K, Adachi K, Fujimoto A, et al
    Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties.
    Oncol Rep. 2017;37:1883-1888.
    PubMed     Text format     Abstract available


    Tumour Biol

  18. YU J, Han Q, Cui Y
    Decreased long non-coding RNA SPRY4-IT1 contributes to ovarian cancer cell metastasis partly via affecting epithelial-mesenchymal transition.
    Tumour Biol. 2017;39:1010428317709129.
    PubMed     Text format     Abstract available

  19. PING H, Guo L, Xi J, Wang D, et al
    Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.
    Tumour Biol. 2017;39:1010428317713389.
    PubMed     Text format     Abstract available

  20. WANG J, Liu Q, Zhou X, He Y, et al
    Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.
    Tumour Biol. 2017;39:1010428317706479.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: